Amba vilas palace, Palace in Mysore, India

New Delhi, June 20 The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation (EUA) to India's first mRNA-based Omicron booster vaccine and it is likely to be rolled out in 2-3 weeks, Gennova Biopharmaceuticals announced on Tuesday.The Pune-based firm's GemCovac-OM is a monovalent needle-free booster shot. It will be delivered intradermally with the PharmaJet Tropis Precision Delivery System (PDS) to adults of 18 years of age and older; and to those who have previously taken the primary vaccine shots from either Covishield or Covaxin, the two major Covid-19 vaccines administered in the country.The GemCovac-OM is a lyophilised (freeze dried) vaccine that remains stable at 2 degrees Celsius to 8 degrees Celsius, and is safe and compatible with the current refrigeration supply chain across India, along with other low and middle-income countries (LMICs), said Dr Sanjay Singh, Chief Executive Officer, Gennova Biopharmaceuticals, at a virtual press conference held on Tuesday."Even though the WHO has declared that Covid is no longer a public health emergency, our booster dose holds relevance as Covid, specifically, Omicron and its sub-lineages are still prevalent. It has been scientifically proven that the existing vaccines are not effective to tackle specific variants. The need is for a tailor-made vaccine to target specific variants," Dr Sanjay Singh said."We are proud to announce that India now has its own Omicron-based vaccine that has passed clinical trials," he added.The mRNA vaccine was developed in association with the Department of Biotechnology. It was evaluated for its safety and immunogenicity as a booster in about 3,000 people from across 13 cities in India who received two doses of Covishield and Covaxin.The clinical trial results showed that the single booster dose is safe and well tolerated with mild to moderate side effects. No serious adverse events were reported.Importantly, GemCovac-OM as a booster also showed "significantly higher immune response than Covishield," Singh said.Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Amba Vilas PalaceFOLLOW

Amba vilas palace, Latest News

Mumbai (Maharashtra) [India], June 20 : International Emmy-nominated anthology 'Lust Stories' is back with its second edition. Makers ... ...

BusinessWire India Chennai (Tamil Nadu) [India], June 20: At a recent event on why prioritising Men's Mental Health is ... ...

GLOBAL PR CONNECT (GPRC) New Delhi [India], June 20: K Raheja Corp Homes, the residential division of K Raheja ... ...

Hyderabad (Telangana) [India], June 20 : Ram Charan's fans just can't keep calm as they welcomed the 'RRR' actor's ... ...

Mumbai (Maharashtra) [India], June 20 : Seems like actors Abhay Deol and Neha Dhupia are reuniting for 'Ek Chalis ... ...

New Delhi [India], June 20 : Swaminathan Janakiraman, Managing Director at State Bank of India, has been appointed Deputy ... ...

Rourkela, June 20 Hockey Chandigarh, Hockey Haryana, Hockey Madhya Pradesh and Hockey Association of Odisha advanced to the ... ...

New Delhi, June 20 The Drugs Controller General of India (DCGI) has granted Emergency Use Authorisation (EUA) to ... ...